News
10-01-2018, 05:20 AM
Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.
More... (https://www.news-medical.net/news/20181001/Phase-3-ECHELON-2-clinical-trial-evaluating-ADCETRIS-plus-CHP-meets-primary-endpoint.aspx)
More... (https://www.news-medical.net/news/20181001/Phase-3-ECHELON-2-clinical-trial-evaluating-ADCETRIS-plus-CHP-meets-primary-endpoint.aspx)